Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 19.81 CNY -0.2% Market Closed
Market Cap: 10.4B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock under the Base Case scenario is 22.78 CNY. Compared to the current market price of 19.81 CNY, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is Undervalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
22.78 CNY
Undervaluation 13%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

11.5
P/S
P/S
Price to Sales
11.5
vs History
93
vs Industry
11
Median 3Y
17.9
Median 5Y
28.8
Industry
2.4
Forward
11
More Details
33.2
P/E
P/E
Price to Earnings
33.2
vs History
93
vs Industry
12
Median 3Y
53.1
Median 5Y
68.6
Industry
20.6
Forward
30.4
More Details
35.7
P/OCF
P/OCF
Price to OCF
35.7
vs History
88
vs Industry
11
Median 3Y
43.8
Median 5Y
67.5
Industry
15.5
More Details
67.5
P/FCFE
P/FCFE
Price to FCFE
67.5
vs History
92
vs Industry
8
Median 3Y
97.3
Median 5Y
129.8
Industry
23
More Details
4.6
P/B
P/B
Price to Book Value
4.6
vs History
93
vs Industry
15
Median 3Y
7.3
Median 5Y
13.4
Industry
1.9
More Details
10.1
EV/S
EV/S
Enterprise Value to Sales
10.1
vs History
93
vs Industry
12
Median 3Y
16.6
Median 5Y
27.5
Industry
2.5
Forward
9.7
More Details
10.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.7
vs History
93
vs Industry
18
Median 3Y
17.5
Median 5Y
29
Industry
4.9
More Details
28.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.2
vs History
93
vs Industry
12
Median 3Y
48.3
Median 5Y
60.9
Industry
12.6
Forward
23.4
More Details
28.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.2
vs History
93
vs Industry
15
Median 3Y
48.3
Median 5Y
60.9
Industry
15.7
Forward
20.7
More Details
31.3
EV/OCF
EV/OCF
Enterprise Value to OCF
31.3
vs History
90
vs Industry
13
Median 3Y
39.9
Median 5Y
64.2
Industry
14
More Details
55.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
55.1
vs History
92
vs Industry
8
Median 3Y
93
Median 5Y
124.5
Industry
17.7
More Details
6.7
EV/IC
EV/IC
Enterprise Value to IC
6.7
vs History
93
vs Industry
12
Median 3Y
11
Median 5Y
24.7
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
10.4B CNY 11.5 33.2 28.2 28.2
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Average P/E: 27
33.2
15%
2.2
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Average EV/EBIT: 1 700.1
28.2
26%
1.1
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 250,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.